5 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
Follow Mucosal Melanoma: new trials by email Literature Review of Mucosal Melanoma trials Research Report on Mucosal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor Pembrolizumab, Vactosertib - Acral Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Yonsei University | 14 | 2023-02-09 | 2025-04-02 |
| Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing - Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Mural Oncology, Inc | 173 | 2021-09-27 | 2025-06-10 |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Nivolumab, Ipilimumab - Acral Lentiginous Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Georgetown University | 14 | 2017-07-26 | 2024-04-04 |
| The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery humanized anti-PD-1 monoclonal antibody Toripalimab, high-dose recombinant interferon a-2B - Mucosal Melanoma | Phase 2 | Terminated | Shanghai Junshi Bioscience Co., Ltd. | 6 | 2017-05-31 | 2026-07-27 |
| Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV temsirolimus, selumetinib, laboratory biomarker analysis - Mucosal Melanoma, Recurrent Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2010-10-01 | 2014-05-15 |
Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Skin Diseases (3) · Skin Neoplasms (3) · Skin and Connective Tissue Diseases (3) · Neoplasms (2)
pembrolizumab (2) · AZD 6244 (1) · Introns (1) · Ipilimumab (1) · Nivolumab (1) · Sirolimus (1) · temsirolimus (1) · vactosertib (1)
Georgetown University (1) · Mural Oncology, Inc (1) · National Cancer Institute (NCI) (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Yonsei University (1)
United States (3) · South Korea (2) · Australia (1) · Canada (1) · China (1) · Italy (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Jun Guo, MD, PhD (1) · Minkyu Jung (1) · Ragini Kudchadkar (1) · Suthee Rapisuwon, MD (1)
P30CA076292 (1)